Repeated systemic administration of human adipose-derived stem cells attenuates overt diabetic nephropathy in rats

Stem Cells and Development

Volumn 22, Issue 23, 2013, Pages 3074-3086

  Zhang, Li ^a   Li, Kanghua ^b   Liu, Xiangfei ^a   Li, Diangeng ^a   Luo, Congjuan ^a   Fu, Bo ^a   Cui, Shaoyuan ^a   Zhu, Fei ^a   Zhao, Robert Chunhua ^b   Chen, Xiangmei ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUCOSE; NEUTRALIZING ANTIBODY; SYNAPTOPODIN;

ACUTE KIDNEY FAILURE; ADIPOSE DERIVED STEM CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOWN REGULATION; HUMAN; HUMAN CELL; MALE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; STREPTOZOCIN DIABETES; UNINEPHRECTOMY;

ADIPOSE TISSUE; ANIMALS; DIABETIC NEPHROPATHIES; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; HYPERGLYCEMIA; HYPERTROPHY; ISLETS OF LANGERHANS; KIDNEY GLOMERULUS; KIDNEY TUBULES; MALE; MICE; PODOCYTES; PROTEINURIA; RATS; RATS, SPRAGUE-DAWLEY; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 84888591498     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2013.0142     Document Type: Article

References (54)

1. IDF Diabetes Atlas Update 2012. Available at www.idf.org/ diabetesatlas/5e/Update2012.
2. Yang W, J Lu, J Weng, W Jia, L Ji, J Xiao, Z Shan, J Liu, H Tian, et al. (2010). China National Diabetes and Metabolic Disorders Study Group. Prevalence of diabetes among men and women in China. N Engl J Med 362:1090-1101.
3. Shaw JE, RA Sicree and PZ Zimmet. Global estimates of the prevalence of diabetes for 2010 and 2030 (2010). Diabetes Res Clin Pract 87:4-14.
4. Molitch ME, RA DeFronzo, MJ Franz, WF Keane, CE Mogensen, HH Parving and MW Steffes; American Diabetes Association. (2004). Nephropathy in diabetes. Diabetes Care 27:S79-S83.
5. Reutens AT and RC Atkins. (2011) Epidemiology of diabetic nephropathy. Contrib Nephrol 170:1-7.
6. Ezquer ME, FE Ezquer, ML Arango-Rodr?guez and PA Conget. (2012). MSC transplantation: a promising therapeutic strategy to manage the onset and progression of diabetic nephropathy. Biol Res 45:289-296.
7. Mizuno H, M Tobita and AC Uysal. (2012). Concise review: adipose-derived stem cells as a novel tool for future regenerative medicine. Stem Cells 30:804-810.
8. Locke M, V Feisst and PR Dunbar. (2011). Concise review: human adipose-derived stem cells: separating promise from clinical need. Stem Cells 29:404-411.
9. Dom?nguez-Bendala J, G Lanzoni, L Inverardi and C Ricordi. (2012). Concise review: mesenchymal stem cells for diabetes. Stem Cells Transl Med 1:59-63.
10. Zuk PA, M Zhu, H Mizuno, J Huang, JW Futrell, AJ Katz, P Benhaim, HP Lorenz and MH Hedrick. (2001). Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 7:211-228.
11. Wickham MQ, GR Erickson, JM Gimble, TP Vail and F Guilak. (2003). Multipotent stromal cells derived from the infrapatellar fat pad of the knee. Clin Orthop 412:196-212.
12. Gimble JM, AJ Katz and BA Bunnell. (2007). Adiposederived stem cells for regenerative medicine. Circ Res 100:1249-1260.
13. Tobita M, H Orbay and H Mizuno. (2011). Adipose-derived stem cells: current findings and future perspectives. Discov Med 11:160-170.
14. Locke M, J Windsor and PR Dunbar. (2009). Human adipose- derived stem cells: isolation, characterization and applications in surgery. Anz J Surg 79:235-244.
15. Lee RH, MJ Seo, RL Reger, JL Spees, AA Pulin, SD Olson and DJ Prockop. (2006) Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci USA 103:17438-17443.
16. Ezquer FE, ME Ezquer, DB Parrau, D Carpio, AJ Yanez and PA Conget. (2008) Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. Biol Blood Marrow Transplant 14:631-640.
17. Ezquer F, M Ezquer, V Simon, F Pardo, A Yanez, D Carpio and P Conget. (2009) Endovenous administration of bonemarrow- derived multipotent mesenchymal stromal cells prevents renal failure in diabetic mice. Biol Blood Marrow Transplant 15:1354-1365.
18. Zhou H, HM Tian, Y Long, XX Zhang, L Zhong, L Deng, XH Chen and XQ Li. (2009) Mesenchymal stem cells transplantation mildly ameliorates experimental diabetic nephropathy in rats. Chin Med J 122:2573-2579.
19. Li K, Q Han, X Yan, L Liao and RC Zhao. (2010). Not a process of simple vicariousness, the differentiation of human adipose-derived mesenchymal stem cells to renal tubular epithelial cells plays an important role in acute kidney injury repairing. Stem Cells Dev 19:1267-1275.
20. Cao Y, Z Sun, L Liao, Y Meng, Q Han and RC Zhao. (2005). Human adipose tissue-derived stem cells differentiate into endothelial cells in vitro and improve postnatal neovascularization in vivo. Biochem Biophys Res Commun 332:370-379.
21. Shi D, L Liao, B Zhang, R Liu, X Dou, J Li, X Zhu, L Yu, D Chen and RC Zhao. (2011). Human adipose tissue-derived mesenchymal stem cells facilitate the immunosuppressive effect of cyclosporin A on T lymphocytes through Jagged-1- mediated inhibition of NF-kB signaling. Exp Hematol 39:214-224.
22. Deng W, Q Han, L Liao, S You, H Deng and RC Zhao. (2005). Effects of allogeneic bone marrow-derived mesenchymal stem cells on T and B lymphocytes from BXSB mice. DNA Cell Biol 24:458-463.
23. Susztak K, AC Raff, M Schiffer and EP Bottinger. (2006). Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 55:225-233.
24. Mankhey RW, F Bhatti and C Maric. (2005). 17b-Estradiol replacement improves renal function and pathology associated with diabetic nephropathy. Am J Physiol Renal Physiol 288:F399-F405.
25. Ninichuk V, O Gross and S Segerer. (2007). Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3- deficient mice. Kidney Int 70:121-129.
26. Caldas HC, IM Fernandes, F Gerbi, AC Souza, MA Baptista, HJ Ramalho, RS Kawasaki-Oyama, EM Goloni-Bertollo, EC Pavarino-Bertelli, DM Braile and M Abbud-Filho. (2008). Effect of whole bone marrow cell infusion in the progression of experimental chronic renal failure. Transplant Proc 40:853-855.
27. Choi S, M Park, J Kim, S Hwang, S Park and Y Lee. (2009). The role of mesenchymal stem cells in the functional improvement of chronic renal failure. Stem Cells Dev18:521-529.
28. Alexandre CS, RA Volpini, MH Shimizu, et al. (2009). Lineage-negative bone marrow cells protect against chronic renal failure. Stem Cells 27:682-692.
29. Pino CJ and HD Humes. (2010). Stem cell technology for the treatment of acute and chronic renal failure. Transl Res 156:161-168.
30. Wang N, Q Li, L Zhang, H Lin, J Hu, D Li, S Shi, S Cui, J Zhou, et al. (2012). Mesenchymal stem cells attenuate peritoneal injury through secretion of TSG-6. PLoS One 7:e43768.
31. Meirelles Lda S, AM Fontes, DT Covas and AI Caplan. (2009) Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev 20:419-427.
32. Mias C, O Lairez, E Trouche, J Roncalli, D Calise, et al. (2009) Mesenchymal stem cells promote matrix metalloproteinase secretion by cardiac fibroblasts and reduce cardiac ventricular fibrosis after myocardial infarction. Stem Cells 27:2734-2743.
33. Yoon BS, JH Moon, EK Jun, J Kim, I Maeng, et al. (2010) Secretory profiles and wound healing effects of human amniotic fluid-derived mesenchymal stem cells. Stem Cells Dev 19:887-902.
34. Lee SR, SH Lee, JY Moon, JY Park, D Lee, SJ Lim, KH Jeong, JK Park, TW Lee and CG Ihm. (2010). Repeated administration of bone marrow-derived mesenchymal stem cells improved the protective effects on a remnant kidney model. Ren Fail 32:840-848.
35. Thomas MC. (2011). Pathogenesis and progression of proteinuria. Contrib Nephrol 170:48-56.
36. Sakoda M, H Itoh and A Ichihara. (2011). Podocytes as a target of prorenin in diabetes. Curr Diabetes Rev 7:17- 21.32
37. White KE. (2006). Research into the glomerular podocyte-is it relevant to diabetic nephropathy? Diabet Med 23:715-719.
38. Durvasula RV and SJ Shankland. (2006). Podocyte injury and targeting therapy: an update. Curr Opin Nephrol Hypertens 15:1-7.
39. Yanagida-Asanuma E, K Asanuma, K Kim, M Donnelly, H Young Choi, J Hyung Chang, S Suetsugu, Y Tomino, T Takenawa, C Faul and P Mundel. (2007). Synaptopodin protects against proteinuria by disrupting Cdc42:IRSp53: mena signaling complexes in kidney podocytes. Am J Pathol 171:415-427.
40. Gross ML, R Dikow and E Ritz. (2005). Diabetic nephropathy: recent insights into the pathophysiology and the progression of diabetic nephropathy. Kidney Int 94:S50-S53.
41. Saleem MA. Biology of the human podocyte (2003). Nephron Exp Nephrol 95:e87-e92.
42. Dalla Vestra M, M Arboit, M Bruseghin, P Fioretto, P Ihalmo, M Wessman and MA Kaunisto. (2008). Association analysis of podocyte slit diaphragm genes as candidates for diabetic nephropathy. Diabetologia 51:86-90.
43. Srichai MB, M Konieczkowski, A Padiyar, DJ Konieczkowski, A Mukherjee, PS Hayden, S Kamat, MA El-Meanawy, S Khan, et al. (2004). A WT1 coregulator controls podocyte phenotype by shuttling between adhesion structures and nucleus. J Biol Chem 279:14398-14408.
44. Kawachi H, N Miyauchi, K Suzuki, GD Han, M Orikasa and F Shimizu. (2006). Role of podocyte slit diaphragm as a filtration barrier. Nephrology (Carlton) 11:274-281.
45. Asanuma K, E Yanagida-Asanuma, C Faul, Y Tomino, K Kim and P Mundel. (2006). Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signalling. Nat Cell Biol 8:485-491.
46. Menini S, C Iacobini, G Oddi, C Ricci, P Simonelli, S Fallucca, M Grattarola, F Pugliese, C Pesce and G Pugliese. (2007). Increased glomerular cell (podocyte) apoptosis in rats with streptozotocin-induced diabetes mellitus: role in the development of diabetic glomerular disease. Diabetologia 50:2591-2599.
47. Miyauchi M, M Toyoda, K Kobayashi, M Abe, T Kobayashi, M Kato, N Yamamoto, M Kimura, T Umezono and D Suzuki. (2009). Hypertrophy and loss of podocytes in diabetic nephropathy. Intern Med 48:1615-1620.
48. Costantini F. (2010). GDNF/Ret signaling and renal branching morphogenesis: from mesenchymal signals to epithelial cell behaviors. Organogenesis 6:252-262.
49. Costantini F and R Shakya. (2006). GDNF/Ret signaling and the development of the kidney. Bioessays 28:117-127.
50. Tsui CC, SJ Shankland and BA Pierchala. (2006). Glial cell line-derived neurotrophic factor and its receptor ret is a novel ligand-receptor complex critical for survival response during podocyte injury. J Am Soc Nephrol 17:1543-1552.
51. Huang ZY, LQ Hong, N Na, Y Luo, B Miao and J Chen. (2012). Infusion of mesenchymal stem cells overexpressing GDNF ameliorates renal function in nephrotoxic serum nephritis. Cell Biochem Funct 30:139-144.
52. Shi H, D Patschan, GP Dietz, M Bä hr, M Plotkin and MS Goligorsky. (2008). Glial cell line-derived neurotrophic growth factor increases motility and survival of cultured mesenchymal stem cells and ameliorates acute kidney injury. Am J Physiol Renal Physiol 294:F229-F235.
53. Rota C, B Imberti, M Pozzobon, M Piccoli, P De Coppi, A Atala, E Gagliardini, C Xinaris, V Benedetti, et al. M. (2012). Human amniotic fluid stem cell preconditioning improves their regenerative potential. Stem Cells Dev 21:1911-1923.
54. Ho JH, TC Tseng, WH Ma, WK Ong, YF Chen, MH Chen, MWLin, CY Hong and OK Lee. (2012). Multiple intravenous transplantations of mesenchymal stem cells effectively restore long-term blood glucose homeostasis by hepatic engraftment and b-cell differentiation in streptozocin-induced diabetic mice. Cell Transplant 21:997-1009.